You are here: Home » Companies » News
Business Standard

Zydus Cadila gets final nod from USFDA for doxycycline tablets

The company will manufacture the drug at the group's formulations facility at the pharma SEZ in Ahmedabad

Press Trust of India  |  New Delhi 

Zydus

Drug firm has received final approval from the US health regulator to market tablets, used for treatment of different types of bacterial infections such as acne and eye infection.

The company has received approval from the (USFDA) to market the drug in strengths of 50 mg, 75 mg, 100 mg and 150 mg, said in a BSE filing today.


The company will manufacture the drug at the group's formulations facility at the pharma SEZ in Ahmedabad.

It has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

The stock of the company's listed entity was up 1.89 per cent at Rs 476 on the BSE today.

First Published: Fri, September 29 2017. 14:46 IST
RECOMMENDED FOR YOU